Herpesvirus Antiviral Resistance
Database


    • TOP

    BIBLIOGRAPHY

    Authors:

  • ______________________
  • Agut H
  • ______________________
  • Aihara T
  • ______________________
  • Aït-Arkoub Z
  • ______________________
  • Alain S
  • ______________________
  • Andouard D
  • ______________________
  • Aranzamendi M
  • ______________________
  • Arens MQ
  • ______________________
  • Asberg A
  • ______________________
  • Ashkenazi S
  • ______________________
  • Attal M
  • ______________________
  • Avery RK
  • ______________________
  • Azzi A
  • ______________________
  • Baldanti F
  • ______________________
  • Balfour HH Jr
  • ______________________
  • Barnard R
  • ______________________
  • Berengua C
  • ______________________
  • Bhorade SM
  • ______________________
  • Biron KK
  • ______________________
  • Bo T
  • ______________________
  • Bodro M
  • ______________________
  • Boivin G
  • ______________________
  • Bono F
  • ______________________
  • Borrell N
  • ______________________
  • Borst E
  • ______________________
  • Bouaziz S
  • ______________________
  • Bour JB
  • ______________________
  • Bourgeois C
  • ______________________
  • Boutolleau D
  • ______________________
  • Bowen EF
  • ______________________
  • Bowlin TL
  • ______________________
  • Bremer JW
  • ______________________
  • Brundage T
  • ______________________
  • Burrel S
  • ______________________
  • Buss NE
  • ______________________
  • Cahen R
  • ______________________
  • Cai GY
  • ______________________
  • Caplan O
  • ______________________
  • Cardinale SC
  • ______________________
  • Cervera C
  • ______________________
  • Champier G
  • ______________________
  • Chemaly RF
  • ______________________
  • Cherrington JM
  • ______________________
  • Chou S
  • ______________________
  • Cihlar T
  • ______________________
  • Coen DM
  • ______________________
  • Cofan F
  • ______________________
  • Colville D
  • ______________________
  • Comeau K
  • ______________________
  • Cordero E
  • ______________________
  • Cotin S
  • ______________________
  • Couvreux A
  • ______________________
  • Covington E
  • ______________________
  • Crumpacker C
  • ______________________
  • Crumpacker CS
  • ______________________
  • Daikoku T
  • ______________________
  • Davis JL
  • ______________________
  • Davis M
  • ______________________
  • Davis MG
  • ______________________
  • Deering M
  • ______________________
  • Denis F
  • ______________________
  • Douglas CM
  • ______________________
  • Drach JC
  • ______________________
  • Drew WL
  • ______________________
  • Drouot E
  • ______________________
  • Ducancelle A
  • ______________________
  • Dunn JP
  • ______________________
  • Eckle T
  • ______________________
  • Efferth T
  • ______________________
  • Eizuru Y
  • ______________________
  • Elston R
  • ______________________
  • Emery VC
  • ______________________
  • Emmer BT
  • ______________________
  • Ercolani RJ
  • ______________________
  • Erice A
  • ______________________
  • Espy MJ
  • ______________________
  • Esteva C
  • ______________________
  • Exner MM
  • ______________________
  • Faizi Khan R
  • ______________________
  • Feghoul L
  • ______________________
  • Fernández Avilés F
  • ______________________
  • Fernández Sabé N
  • ______________________
  • Fischer L
  • ______________________
  • Follansbee SE
  • ______________________
  • Forman MS
  • ______________________
  • Foster S
  • ______________________
  • Fournier M
  • ______________________
  • Frobert E
  • ______________________
  • Fuller MD
  • ______________________
  • Furione M
  • ______________________
  • Garrigue I
  • ______________________
  • Garrity ER
  • ______________________
  • Gaudreau A
  • ______________________
  • Gerna G
  • ______________________
  • Giannotti F
  • ______________________
  • Gil-Roda C
  • ______________________
  • Gilbert C
  • ______________________
  • Giller RH
  • ______________________
  • Göhring K
  • ______________________
  • Goldner T
  • ______________________
  • Goyette N
  • ______________________
  • Greenfield I
  • ______________________
  • Griffiths PD
  • ______________________
  • Guentzel S
  • ______________________
  • Hakki M
  • ______________________
  • Haller T
  • ______________________
  • Hamprecht K
  • ______________________
  • Handgretinger R
  • ______________________
  • Hanson MN
  • ______________________
  • Hantz S
  • ______________________
  • Hartline CB
  • ______________________
  • Hartmann A
  • ______________________
  • Hempel C
  • ______________________
  • Hofmann J
  • ______________________
  • Höhn S
  • ______________________
  • Holder D
  • ______________________
  • Honigman A
  • ______________________
  • Hosoi H
  • ______________________
  • Hu H
  • ______________________
  • Humar A
  • ______________________
  • Ikeda M
  • ______________________
  • Imrich E
  • ______________________
  • Isaacs MA
  • ______________________
  • Isada CM
  • ______________________
  • Ives J
  • ______________________
  • Jabs DA
  • ______________________
  • Jahn G
  • ______________________
  • James SH
  • ______________________
  • Jardine AG
  • ______________________
  • Johnson MA
  • ______________________
  • Jun D
  • ______________________
  • Kaiser L
  • ______________________
  • Kemble GW
  • ______________________
  • Kesson AM
  • ______________________
  • Khan AR
  • ______________________
  • Kleiboeker S
  • ______________________
  • Klingebiel T
  • ______________________
  • Kohn DJ
  • ______________________
  • Komazin G
  • ______________________
  • Komazin-Meredith G
  • ______________________
  • Kotton CN
  • ______________________
  • Kumura Ishii K
  • ______________________
  • Laib Sampaio K
  • ______________________
  • Lalezari JP
  • ______________________
  • Lamy PD
  • ______________________
  • Lanier ER
  • ______________________
  • Le Pors MJ
  • ______________________
  • Leavitt R
  • ______________________
  • Lebel MH
  • ______________________
  • Lefterova MI
  • ______________________
  • Len O
  • ______________________
  • Lepiller Q
  • ______________________
  • Levitan D
  • ______________________
  • Li S
  • ______________________
  • Li W
  • ______________________
  • Ligat G
  • ______________________
  • Lin SX
  • ______________________
  • Linares L
  • ______________________
  • Lischka P
  • ______________________
  • Lundgren J
  • ______________________
  • Lurain NS
  • ______________________
  • Maguire M
  • ______________________
  • Marcos MÁ
  • ______________________
  • Marfori JE
  • ______________________
  • Marousek G
  • ______________________
  • Marousek GI
  • ______________________
  • Marschall M
  • ______________________
  • Martin BK
  • ______________________
  • Martin M
  • ______________________
  • Martin-Davila P
  • ______________________
  • Masouridi-Levrat S
  • ______________________
  • Mazeron MC
  • ______________________
  • Mendez JC
  • ______________________
  • Mengelle C
  • ______________________
  • Mertens T
  • ______________________
  • Merville P
  • ______________________
  • Messerle M
  • ______________________
  • Michel D
  • ______________________
  • Michels KS
  • ______________________
  • Miller WJ
  • ______________________
  • Minamishima Y
  • ______________________
  • Miner RC
  • ______________________
  • Mirand A
  • ______________________
  • Mommeja-Marin H
  • ______________________
  • Moreno A
  • ______________________
  • Mori S
  • ______________________
  • Mosquera MM
  • ______________________
  • Mulato AS
  • ______________________
  • Mullen MG
  • ______________________
  • Muller C
  • ______________________
  • Murray RA
  • ______________________
  • Navarro Gabriel M
  • ______________________
  • Neumann AU
  • ______________________
  • Nickle D
  • ______________________
  • Nishida T
  • ______________________
  • Palù G
  • ______________________
  • Papanicolaou GA
  • ______________________
  • Paya CV
  • ______________________
  • Peet NP
  • ______________________
  • Pereira MR
  • ______________________
  • Pérez Jiménez AB
  • ______________________
  • Pérez JL
  • ______________________
  • Pescovitz MD
  • ______________________
  • Petit F
  • ______________________
  • Pham VD
  • ______________________
  • Pilorgé L
  • ______________________
  • Pinsky BA
  • ______________________
  • Piret J
  • ______________________
  • Plault N
  • ______________________
  • Poscher ME
  • ______________________
  • Pothier P
  • ______________________
  • Pouteil-Noble C
  • ______________________
  • Price NB
  • ______________________
  • Prichard MN
  • ______________________
  • Prix L
  • ______________________
  • Ptak RG
  • ______________________
  • Pursell KJ
  • ______________________
  • Quinones R
  • ______________________
  • Rametti A
  • ______________________
  • Rawlinson WD
  • ______________________
  • Resnick IB
  • ______________________
  • Robert ES
  • ______________________
  • Roberts NA
  • ______________________
  • Rodríguez C
  • ______________________
  • Rollag H
  • ______________________
  • Rovira M
  • ______________________
  • Ruebsamen-Schaeff H
  • ______________________
  • Sahoo MK
  • ______________________
  • Saito K
  • ______________________
  • Saleh N
  • ______________________
  • Salmier A
  • ______________________
  • Sampaio KL
  • ______________________
  • Sánchez-Palomino S
  • ______________________
  • Sannerud KJ
  • ______________________
  • Santos Bravo M
  • ______________________
  • Sarasini A
  • ______________________
  • Satterwhite LE
  • ______________________
  • Schibler M
  • ______________________
  • Scott GM
  • ______________________
  • Selle B
  • ______________________
  • Senters AE
  • ______________________
  • Shapira MY
  • ______________________
  • Sharma PL
  • ______________________
  • Shi R
  • ______________________
  • Shira JE
  • ______________________
  • Shiraki K
  • ______________________
  • Sia IG
  • ______________________
  • Sidorov E
  • ______________________
  • Silini E
  • ______________________
  • Simoncini L
  • ______________________
  • Sixt N
  • ______________________
  • Smith TF
  • ______________________
  • Song K
  • ______________________
  • Springer KL
  • ______________________
  • Stamminger T
  • ______________________
  • Stanat SC
  • ______________________
  • Strasfeld LM
  • ______________________
  • Strizki J
  • ______________________
  • Stuppfler S
  • ______________________
  • Suarez-Lledó M
  • ______________________
  • Sudlow R
  • ______________________
  • Sullivan V
  • ______________________
  • Taege AJ
  • ______________________
  • Takahashi Y
  • ______________________
  • Takemoto M
  • ______________________
  • Talarico CL
  • ______________________
  • Tau KR
  • ______________________
  • Teal V
  • ______________________
  • Thompson KD
  • ______________________
  • Tilloy V
  • ______________________
  • Todd KM
  • ______________________
  • Townsend LB
  • ______________________
  • Trapes L
  • ______________________
  • Underwood MR
  • ______________________
  • van Alewijk DCJG
  • ______________________
  • van Doorn LJ
  • ______________________
  • Van Wechel LC
  • ______________________
  • Vidal E
  • ______________________
  • Viget N
  • ______________________
  • Villano S
  • ______________________
  • Waldemer RH
  • ______________________
  • Wan H
  • ______________________
  • Watanabe J
  • ______________________
  • Wechel LC
  • ______________________
  • Weinberg A
  • ______________________
  • Weinberg DV
  • ______________________
  • Williams JD
  • ______________________
  • Wilson C
  • ______________________
  • Wolf DG
  • ______________________
  • Wu J
  • ______________________
  • Wu JJ
  • ______________________
  • Yaniv I
  • ______________________
  • Yasdanpanah Y
  • ______________________
  • Yeldandi VV
  • ______________________
  • Yen-Lieberman B
  • ______________________
  • Zeng F
  • ______________________
  • Zimmermann H

    • References:

  • A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000).
  • A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006).
  • A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998).
  • A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. (Sep 1992).
  • A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017).
  • A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. (Feb 1995).
  • Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008).
  • Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. (Sep 2001).
  • Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020).
  • Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002).
  • Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016).
  • Antiviral drug resistance of human cytomegalovirus. (Oct 2010).
  • Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015).
  • Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997).
  • Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008).
  • Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998).
  • Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006).
  • Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014).
  • Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017).
  • Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019).
  • Conserved domains and structure prediction of human cytomegalovirus UL27 protein. ( 2009).
  • Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008).
  • Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016).
  • Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012).
  • Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004).
  • Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009).
  • Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013).
  • Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007).
  • Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011).
  • Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002).
  • Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007).
  • Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009).
  • Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024).
  • Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000).
  • Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012).
  • Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient. (May 1998).
  • Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. (Feb 2001).
  • Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997).
  • First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022).
  • Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024).
  • Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. (Aug 1998).
  • Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013).
  • Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998).
  • Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014).
  • Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022).
  • Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007).
  • How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005).
  • Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014).
  • Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014).
  • Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016).
  • Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014).
  • Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010).
  • Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999).
  • Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020).
  • Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. (Nov 2001).
  • Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007).
  • Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003).
  • Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004).
  • New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. ( 2007).
  • New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018).
  • Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016).
  • Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013).
  • Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. (Mar 1999).
  • Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019).
  • Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011).
  • Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014).
  • Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008).
  • Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. (Aug 1999).
  • Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013).
  • Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015).
  • Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001).
  • Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011).
  • Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010).
  • Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. (May-Aug 2003).
  • Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013).
  • Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001).
  • Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996).
  • Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. (Sep 1997).
  • Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003).

    • Journal:

  • AIDS (London, England)
  • American journal of ophthalmology
  • Antimicrobial agents and chemotherapy
  • Antiviral research
  • Antiviral therapy
  • Blood
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • Clinical microbiology reviews
  • Computational and structural biotechnology journal
  • Journal of clinical microbiology
  • Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • Journal of medical virology
  • Journal of virological methods
  • Journal of virology
  • Microbiology and immunology
  • Nature
  • Nucleosides, nucleotides & nucleic acids
  • The Journal of infectious diseases
  • Transplantation
  • Virology